AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Serbia opens Israeli drone factory as defense ties with Elbit deepen
2
“Our next milestone will be a billion-dollar valuation”: MIND triples valuation to $300 million with $72 million Series B
3
The man who helped build Palo Alto’s Cortex is leaving the company
4
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
5
Sayeret Matkal veterans raise $22 million to teach the world English with AI
More news

Gilead Sciences

5 stories about Gilead Sciences
יוהן אלבז

Investments are flowing into synthetic biology - the red-hot field that will change the world

28.07.21|Sophie Shulman
Synthetic biology seemed like science fiction until the arrival of the coronavirus vaccines. But now the money has begun to flow and companies are revealing remarkable inventions: from bacteria that will attack tumors to shoes made of cobwebs
משרדי בורסת נאסד"ק ב ניו יורק

ForeBio is on its way to Nasdaq at a $500 million valuation

01.03.21|Tzally Greenberg
The company aims to raise $100 million in an April IPO, while Pontifax and OrbiMed who previously invested $21 million for a 12.5% stake in ForeBio’s shares are expected to make a $120 million profit
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
מוסף שבועי 14.9.17 פרופ' גידי גרוס

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur